The Latest Breaking News from Alkermes

Owing to the critical medical needs, the lookout for new technologies to deal with future advancements is at its peak. Breakthrough innovations, revolutionary treatments, and a booming industry align to make biotech stocks a potential goldmine for savvy investors. Therefore, it could be wise to invest in quality biotech stocks…

Strong recent economic data and still-elevated inflation are expected to keep the Fed on track for another interest rate hike next month. With the stock market likely to remain volatile amid rising interest rates and other macro uncertainties, fundamentally sound stocks Astellas (ALPMY), Alkermes (ALKS), and AstroNova (ALOT), trading at…

Alkermes shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

A Relative Strength Rating upgrade for Alkermes shows improving technical performance.

Seattle Genetics and Alkermes beat fourth-quarter estimates Thursday, pushing Alkermes stock into a brief breakout as SGEN stock soared.

Upgrades

 

Change Healthcare Inc. (NASDAQ: CHNG) reported first-quarter fiscal 2023 adjusted earnings per share (ETF:EPS) of 38 cents, which missed the Zacks Consensus Estimate of 39 cents by 2.6%. The bottom line declined 7.3% on a year-over-year basis.

The top five biotech stocks today have several commonalities. Among them are strong ratings. Some show promising charts and are Tech Leaders.

A few names from the global stock screen are worth mentioning.

GSK announced positive results in a late-stage study on a new Covid-19 vaccine targeted to combat the omicron variant.